First-ever rapid-acting insulin. This approval extends to a 3-milliliter single-patient-use prefilled pen and a 10-milliliter ...

Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

So far, five biosimilars that reference Eylea 2 mg have been approved by the FDA. Alvotech/Teva expect to regulatory approval ...

Nearly two-thirds (64%)  of Americans who have tried weight loss injections report the drugs as being “extremely effective” or “effective.” A pressing question for many users of GLP-1 receptor agonist ...

Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...

The expected out-of-pocket costs for commonly used drugs like Eliquis and Ozempic have surged for Medicare beneficiaries in ...

“Any obesity is a big risk for high blood pressure but, again, abdominal fat is an especially big contributor,” says Chiesa. ...

A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...

Using one word, how would you describe the Medicare health insurance landscape in the U.S.? Dizzying? Maybe. Overwhelming?

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...